Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Double Blind,Placebo-controlled,Parallel Group,Repeat Dose Study of the Safety and Efficacy of REGN475 in Patients With Osteoarthritis of the Knee

NCT00944892 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT00944892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00944892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Double Blind,Placebo-controlled,Parallel Group,Repeat Dose Study of the Safety and Efficacy of REGN475 in Patients With Osteoarthritis of the Knee
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2009
Completion date
May 31, 2010
Enrollment
200 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee